University of Wisconsin–Madison

UW Madison Psychedelic Symposium

Developed & Conducted by the University of Wisconsin-Madison Transdisciplinary Center for Research in Psychoactive Substances and the Division of Pharmacy Professional Development, School of Pharmacy, University of Wisconsin-Madison.

The University of Wisconsin Madison Transdisciplinary Center for Research in Psychoactive Substances held the Psychedelic Symposium in November 2021. The lectures were recorded and are now offered as an enduring CE program.

The Symposium highlighted scholarly work being performed in this field at the UW-Madison and featured nationally renowned keynote speakers. It is intended for researchers and clinicians in the areas of clinical psychology, psychiatry, pharmacy, and nursing, and offers continuing education hours.

The Symposium includes updates on the use psilocybin for depression and substance use disorders. The phenomenology of psychedelic experiences is discussed, as well as historical, environmental, and cultural implications of the use of traditional psychedelics. Barriers to access to this clinical research that exist for underserved populations will be explored, along with suggestions to address these barriers and expand access in future research.

Session topics include:

  • Psychedelic Wars: Past and Present
  • Psychedelics in Latin America and the case of the Intercultural Clinic in Sonora, Mexico
  • Neuropharmacology of Psychedelic Action
  • Environmental Influences on Psilocybin Outcomes Across Species
  • Psilocybin in the Treatment of Addictive Disorders
  • Psychedelics in the Treatment of Depression
  • The Phenomenology of Psychedelics

This program is made possible in part through financial support from MidMed, Tryp Therapeutics, Usona Institute and WARF.

Registration Information

Register

Refund Policy

Course date:Jan 1, 2022 - Nov 30, 2022
Location:
Course fee:

Registration now open.

Course opens January 1, 2022

$100

Course Objectives

As a result of participating in this symposium, learners should be able to:

  • Describe the neuropharmacology of psilocybin and MDMA, noting their similaries and differences.
  • Describe the common and rarer but serious adverse effects of psilocybin and MDMA, and other related drugs.
  • Describe the processes of patient selection, preparation, and treatment, and how these are intended to minimize adverse effects and maximize therapeutic benefits.
  • Describe the cultural, historic, and socioeconomic barriers to therapeutic treatments with psychedelics.
  • Describe the steps for developing a drug for FDA approval, and how the process for psilocybin and MDMA is likely to be different from related psychoactive drugs.
  • Describe the different chemical classes of psychedelics, including similarities and differences in effect and time course of effect.

Course Outline

Presentations
Lecture 1

What in the World is Going on with Psychedelic Research?

Speaker: Paul Hutson, PharmD, BCOP, Professor (CHS), Pharmacy Practice Division, University of Wisconsin-Madison School of Pharmacy

Lecture 2

Psychedelic Wars: Past and Present 

Speaker: Lucas Richert, PhD, Associate Professor,  George Urdang Chair in the History of Pharmacy Director of Graduate Studies, Health Services Research in Pharmacy Graduate Program, University of Wisconsin-Madison, School of Pharmacy

Lecture 3

Psychedelics in Latin America 

Speaker: Alberto Vargas, PhD, Associate Director Latin American, Caribbean and Iberian Studies Program, University of Wisconsin-Madison

Lecture 4

Intercultural Medicine Clinic Project: The Use of Culturally-Adapted Entheogenic Medicines to Treat Substance Use Disorders and Other Mental Health Challenges in the Yaqui Tribe
Speaker: Ana Ortiz Bernal, PhD Candidate

Lecture 5

Classic Psychedelics as Novel Therapeutics for Substance Use Disorders: Special Considerations for Vulnerable Populations

Speaker: Peter S. Hendricks, PhD, (Clinical Psychologist), Professor & Director of Research, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham

Lecture 6

Ketamine Assisted Psychotherapy: Therapeutic Use & Clinical Indications

Speaker: Chantelle Thomas, PhD,  Research Associate, Department of Family Medicine and Community Health, School of Medicine and Public Health, Madison, Wisconsin, and Executive Clinical Director, Windrose Recovery, Brookfield, Wisconsin

Lecture 7

Current UW Research into Psychedelic Compounds for Substance Use Disorders

Speaker: Randy Brown, MD, PhD, DFASAM, Associate Professor with Tenure, Department of Family Medicine and Community Health; Director, University of Wisconsin Addiction Medicine Fellowship Training Program, University of Wisconsin School of Medicine and Public Health, Staff Addictionologist, HIV Comprehensive Care Center University of Wisconsin Hospital and Clinics

Lecture 8

Beyond Mysticism: the Phenomenology of Psychedelics

Speaker: John Dunne, PhD, Distinguished Professor of Contemplative Humanities, Chair Department of Asian Languages & Cultures and Core Faculty, Center for Healthy Minds, University of Wisconsin-Madison

Lecture 9

Psychedelic Substances in the Treatment of Depression   

Speaker: Charles L. Raison, MD, Mary Sue and Mike Shannon Distinguished Chair for Healthy Minds, Children & Families, Professor, School of Human Ecology, and Professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison

Lecture 10

From Stress to Self-Identity: Environmental Influences on Psilocybin Outcomes Across Species

Speaker: Cody Wenthur, PharmD, PhD, Assistant Professor and Director, MS in Psychoactive, Pharmaceutical Investigation, University of Wisconsin-Madison School of Pharmacy

Lecture 11

The Short and Long of it: Acute and Post-Acute Effects of Ketamine and Classical Psychedelics on Brain Activity and Connectivity

Speaker: Matthew Banks, PhD, Professor, School of Medicine and Public Health

Lecture 12

Changes in Synaptic Excitability Following Psychedelic Administration

Speaker: Zarmeen Zahid, PhD Candidate, UW Neuroscience Training Program

Lecture 13

Effects of Ketamine and Psilocybin on Fear Acquisition and Extinction in Mice

Speaker: John Razidlo, PhD Candidate, UW Neuroscience Training Program

   

Instructors

Matthew Banks, PhD, Professor, School of Medicine and Public Health, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Randy Brown, MD, PhD, DFASAM, Associate Professor with Tenure, Department of Family Medicine and Community Health; Director, University of Wisconsin Addiction Medicine Fellowship Training Program, University of Wisconsin School of Medicine and Public Health; Staff Addictionologist, HIV Comprehensive Care Center University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: Yes

John Dunne, PhD, Distinguished Professor of Contemplative Humanities, Chair Department of Asian Languages & Cultures and Core Faculty, Center for Healthy Minds, University of Wisconsin-Madison, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Peter S. Hendricks, PhD, (Clinical Psychologist), Professor & Director of Research, Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, Birmingham, AL
Financial Relationship Disclosure: Bright Minds Biosciences Ltd. (Contractor), Eleusis Benefit Corporation (Contractor),Reset Pharmaceuticals Inc. (Contractor),Silo Pharma Inc (Contractor)
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Paul Hutson, PharmD, BCOP, Professor, Pharmacy Practice Division, UW-Madison School of Pharmacy, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: Yes

Ana Ortiz, Associate Researcher, PhD Candidate, School of Human Ecology, Associate Researcher, School of Medicine and Public Health, Project Development Coordinator, Yaqui Intercultural Medicine Clinic, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Charles L. Raison, MD, Mary Sue and Mike Shannon Distinguished Chair for Healthy Minds, Children & Families, Professor, School of Human Ecology, and Professor, Department of Psychiatry, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI
Financial Relationship Disclosure: Usona Institute (Contractor),Otsuka America Pharmaceutical (Contractor),Novartis (Contractor), Alfasigma USA, Inc. (Contractor)
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: Yes

John Razidlo, PhD Candidate, University of WI Neuroscience Training Program, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: Yes

Lucas Richert, PhD, Associate Professor,  George Urdang Chair in the History of Pharmacy Director of Graduate Studies, Health Services Research in Pharmacy Graduate Program, UW Madison School of Pharmacy, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Chantelle Thomas, PhD,  Research Associate, Department of Family Medicine and Community Health, School of Medicine and Public Health, Madison, Wisconsin, and Executive Clinical Director, Windrose Recovery, Brookfield, Wisconsin
Financial Relationship Disclosure: Windrose counseling (Employment)
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Alberto Vargas, PhD, Associate Director Latin American, Caribbean and Iberian   Studies Program, University of Wisconsin-Madison
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: No

Cody Wenthur, PharmD, PhD, Assistant Professor and Director, MS in Psychoactive, Pharmaceutical Investigation, University of Wisconsin-Madison School of Pharmacy, Madison, WI
Financial Relationship Disclosure: Kadmon Corporation LLC (Stock), Psyence (Contractor),chinook therapeutics (Stock), provention bio (Stock),MAIA Life Sciences (Contractor),Ohio Attorney General's Office (Contractor), Scynexis Inc. (Stock), Usona Institute (Grant)
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: Yes

Zarmeen Zahid, PhD Candidate, University of WI Neuroscience Training Program, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose
Discussion of Unlabeled/Unapproved Uses of Drugs/Devices in Presentation: Yes

 

Planning Committee

Paul Hutson, PharmD, BCOP, Professor, Pharmacy Practice Division, UW-Madison School of Pharmacy, Madison, WI
Financial Relationship Disclosure: See above

Megan Miller, PhD, RN, Postdoctoral Research Associate,  UW-Madison School of Nursing, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose

Christopher Nicholas, PhD, Assistant Professor (CHS), Clinical Psychologist, School of Medicine and Public Health, Madison, WI
Financial Relationship Disclosure: See above

Charles Raison, MD, Professor, UW-Madison School of Human Ecology, Madison, WI
Financial Relationship Disclosure: See above

Lucas Richert, PhD, Associate Professor, Social and Administrative Sciences Division, George Urdang Chair in the History of Pharmacy, Driector of Graduate Studies, Health Services Research in Pharmacy Graduate Program, UW-Madison  School of Pharmacy, Madison, WI
Financial Relationship Disclosure: See above

Cody Wenthur, PharmD, PhD, Assistant Professor, Pharmacy Practice Division, UW-Madison School of Pharmacy, Madison, WI
Financial Relationship Disclosure: See above

Angela Willits, MSW, LCSW, Clinical Assistant Professor, MSW Program Director, UW-Madison School of Social Work, Madison, WI
Financial Relationship Disclosure: No financial relationships with ineligible companies to disclose

Policy on Faculty and Sponsor Disclosure

It is the policy of the University of Wisconsin – Madison Interprofessional Continuing Education Partnership (ICEP) to identify, mitigate and disclose all relevant financial relationships, with ineligible companies* held by speakers/presenters, authors, planners, and other persons who may influence content of this continuing education (CE).  In addition, speakers/presenters and authors must also disclose any planned discussion of unlabeled/unapproved uses of drugs or devices during their presentation(s). 

*Ineligible companies are those whose primary business is producing, marketing, re-selling, or distributing healthcare products used by, or on, patients. ACCME does not consider providers of clinical services directly to patients to be ineligible companies.

CE Credit

ICEP LogoAccreditation Statement

In support of improving patient care, the University of Wisconsin–Madison ICEP is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

Accreditation Council for Pharmacy Education (ACPE)

The University of Wisconsin–Madison ICEP designates this live knowledge based activity for 10.00 hours or 0.10 CEUs of CPE credit. Credit can be earned by successfully completing the activity, the assessment and the evaluation. There will be no partial credit awarded for partial completion.

Live CEU's: ACPE# JA0000358-0000-22-152-H04-P (7.0  hours/0.7 CEU's)

American Medical Association (AMA)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credit(s)™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC)

The University of Wisconsin–Madison ICEP designates this live activity for a maximum of 7.0 ANCC contact hours.

American Psychological Association (APA)

Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibly for the content of the programs.

Continuing Education Units (CEUs)

The University of Wisconsin–Madison ICEP, as a member of the University Professional & Continuing Education Association (UPCEA), authorizes this program for 0.10 CEUs or 7.0 hours.

Program Coordinator

Eric Buxton, PhD

Division of Pharmacy Professional Development
777 Highland Avenue
Madison, WI 53705
(608) 262-2431 FAX
(608) 265-2259
eric.buxton@wisc.edu